CA2986956C - An immune cell comprising a car and truncated protein - Google Patents
An immune cell comprising a car and truncated protein Download PDFInfo
- Publication number
- CA2986956C CA2986956C CA2986956A CA2986956A CA2986956C CA 2986956 C CA2986956 C CA 2986956C CA 2986956 A CA2986956 A CA 2986956A CA 2986956 A CA2986956 A CA 2986956A CA 2986956 C CA2986956 C CA 2986956C
- Authority
- CA
- Canada
- Prior art keywords
- domain
- protein
- cell
- cells
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 170
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 166
- 210000002865 immune cell Anatomy 0.000 title claims description 23
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 186
- 102000014400 SH2 domains Human genes 0.000 claims abstract description 100
- 108050003452 SH2 domains Proteins 0.000 claims abstract description 100
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 44
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 44
- 230000005764 inhibitory process Effects 0.000 claims abstract description 27
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims abstract description 21
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims abstract description 21
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 122
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 121
- 150000007523 nucleic acids Chemical class 0.000 claims description 99
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 56
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 51
- 108020004707 nucleic acids Proteins 0.000 claims description 51
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 48
- 239000013598 vector Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 claims description 8
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 5
- 238000010361 transduction Methods 0.000 claims description 5
- 230000026683 transduction Effects 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 abstract description 153
- 102000037865 fusion proteins Human genes 0.000 abstract description 153
- 230000004913 activation Effects 0.000 abstract description 59
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 28
- 102000020233 phosphotransferase Human genes 0.000 abstract description 28
- 230000019491 signal transduction Effects 0.000 abstract description 19
- 235000018102 proteins Nutrition 0.000 description 147
- 210000004027 cell Anatomy 0.000 description 128
- 210000001744 T-lymphocyte Anatomy 0.000 description 101
- 108091005804 Peptidases Proteins 0.000 description 95
- 239000004365 Protease Substances 0.000 description 95
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 95
- 230000002401 inhibitory effect Effects 0.000 description 89
- 239000000427 antigen Substances 0.000 description 74
- 102000036639 antigens Human genes 0.000 description 73
- 108091007433 antigens Proteins 0.000 description 73
- 238000003776 cleavage reaction Methods 0.000 description 72
- 230000007017 scission Effects 0.000 description 72
- 102000005962 receptors Human genes 0.000 description 71
- 108020003175 receptors Proteins 0.000 description 71
- 230000011664 signaling Effects 0.000 description 67
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 53
- 108091023040 Transcription factor Proteins 0.000 description 44
- 102000040945 Transcription factor Human genes 0.000 description 44
- 239000012528 membrane Substances 0.000 description 44
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 43
- 108091008874 T cell receptors Proteins 0.000 description 42
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 42
- 235000002374 tyrosine Nutrition 0.000 description 40
- 230000003213 activating effect Effects 0.000 description 39
- 230000004927 fusion Effects 0.000 description 35
- 108091008611 Protein Kinase B Proteins 0.000 description 31
- 241000723792 Tobacco etch virus Species 0.000 description 30
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 27
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 23
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 23
- 125000006850 spacer group Chemical group 0.000 description 22
- 210000000822 natural killer cell Anatomy 0.000 description 21
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 20
- 230000006044 T cell activation Effects 0.000 description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 230000026731 phosphorylation Effects 0.000 description 15
- 238000006366 phosphorylation reaction Methods 0.000 description 15
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 14
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- -1 BTLA4 Proteins 0.000 description 12
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 12
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 12
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 12
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 11
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 10
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 description 10
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 description 10
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 10
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 10
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 10
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 10
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 10
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 10
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 10
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 10
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 10
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 10
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 10
- 210000003289 regulatory T cell Anatomy 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 102000015617 Janus Kinases Human genes 0.000 description 8
- 108010024121 Janus Kinases Proteins 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000002964 excitative effect Effects 0.000 description 8
- 108091008042 inhibitory receptors Proteins 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000005220 cytoplasmic tail Anatomy 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 230000007115 recruitment Effects 0.000 description 7
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 6
- 108010076818 TEV protease Proteins 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000004068 intracellular signaling Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 5
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 5
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 5
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 5
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 5
- 230000006786 activation induced cell death Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 102000027596 immune receptors Human genes 0.000 description 5
- 108091008915 immune receptors Proteins 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 4
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 108020001778 catalytic domains Proteins 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 101150098203 grb2 gene Proteins 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101000608750 Arachis hypogaea Alpha-methyl-mannoside-specific lectin Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108010019437 Janus Kinase 2 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102100040207 Poly(A) polymerase beta Human genes 0.000 description 3
- 101710192595 Polyamine aminopropyltransferase Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 230000010799 Receptor Interactions Effects 0.000 description 3
- 101000771730 Tropidolaemus wagleri Waglerin-3 Proteins 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010052015 cytokine release syndrome Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108010000837 Janus Kinase 1 Proteins 0.000 description 2
- 108010019421 Janus Kinase 3 Proteins 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108010010057 TYK2 Kinase Proteins 0.000 description 2
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 102000055193 human ZAP70 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000002602 induced regulatory T cell Anatomy 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000000803 paradoxical effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- TYKASZBHFXBROF-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(2,5-dioxopyrrol-1-yl)acetate Chemical compound O=C1CCC(=O)N1OC(=O)CN1C(=O)C=CC1=O TYKASZBHFXBROF-UHFFFAOYSA-N 0.000 description 1
- XYYHNDVKALDFHQ-OXHZBIAZSA-N 1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC XYYHNDVKALDFHQ-OXHZBIAZSA-N 0.000 description 1
- LWSOZPNJUFEDJU-UHFFFAOYSA-N 2-[4-(1,3-benzoxazol-2-yl)-2-methoxyphenyl]acetonitrile Chemical compound C1=C(CC#N)C(OC)=CC(C=2OC3=CC=CC=C3N=2)=C1 LWSOZPNJUFEDJU-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101150027879 FOXP3 gene Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102100023413 GRB2-related adapter protein Human genes 0.000 description 1
- 101100229073 Gallus gallus GAL5 gene Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 102000004989 Hepsin Human genes 0.000 description 1
- 108090001101 Hepsin Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000829735 Homo sapiens GRB2-related adapter protein Proteins 0.000 description 1
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001069691 Homo sapiens Protogenin Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100033834 Protogenin Human genes 0.000 description 1
- 101100190856 Rauvolfia serpentina PNAE gene Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 101100029551 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGM2 gene Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100023102 Solute carrier family 22 member 18 Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 101710098414 Tyrosine-protein phosphatase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000025188 carcinoma of pharynx Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 102000044858 human PTPN11 Human genes 0.000 description 1
- 102000044716 human PTPN6 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1509413.9A GB201509413D0 (en) | 2015-06-01 | 2015-06-01 | Fusion protein |
| GB1509413.9 | 2015-06-01 | ||
| PCT/GB2016/051576 WO2016193696A1 (en) | 2015-06-01 | 2016-05-31 | Cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2986956A1 CA2986956A1 (en) | 2016-12-08 |
| CA2986956C true CA2986956C (en) | 2022-03-22 |
Family
ID=53677545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2986956A Active CA2986956C (en) | 2015-06-01 | 2016-05-31 | An immune cell comprising a car and truncated protein |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11345734B2 (enExample) |
| EP (2) | EP3730609A1 (enExample) |
| JP (4) | JP6833727B2 (enExample) |
| KR (1) | KR102275460B1 (enExample) |
| CN (1) | CN107667170B (enExample) |
| AU (1) | AU2016272457B2 (enExample) |
| BR (1) | BR112017023190A2 (enExample) |
| CA (1) | CA2986956C (enExample) |
| CL (1) | CL2017003057A1 (enExample) |
| DK (1) | DK3303568T3 (enExample) |
| ES (1) | ES2791338T3 (enExample) |
| GB (1) | GB201509413D0 (enExample) |
| HU (1) | HUE050132T2 (enExample) |
| IL (1) | IL255594B (enExample) |
| MX (1) | MX383118B (enExample) |
| PL (1) | PL3303568T3 (enExample) |
| PT (1) | PT3303568T (enExample) |
| RU (1) | RU2729158C2 (enExample) |
| WO (1) | WO2016193696A1 (enExample) |
| ZA (1) | ZA201707334B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| CN108025024B (zh) | 2015-07-28 | 2022-11-29 | 宾夕法尼亚大学董事会 | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 |
| BR112018013679A2 (pt) | 2016-01-11 | 2019-01-22 | Univ Leland Stanford Junior | proteínas quiméricas e métodos de regulação de expressão gênica |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| GB201620070D0 (en) * | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| GB201621889D0 (en) * | 2016-12-21 | 2017-02-01 | Autolus Ltd | Cell |
| US20230159619A1 (en) * | 2017-02-23 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Compositions and methods for regulating immune system activity |
| EP3589647A1 (en) * | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| GB201707783D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| AU2018270078A1 (en) * | 2017-05-15 | 2019-11-07 | Autolus Limited | A cell comprising a chimeric antigen receptor (CAR) |
| US20200306303A1 (en) * | 2017-09-29 | 2020-10-01 | Chiou Hwa YUH | Methods and compositions enhancing survival and functionality of anti-tumor and anti-viral t cells |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| WO2019118518A2 (en) * | 2017-12-11 | 2019-06-20 | Senti Biosciences, Inc. | Inducible cell receptors for cell-based therapeutics |
| EP3810753A1 (en) * | 2018-06-19 | 2021-04-28 | Autolus Limited | Cell |
| CN109294982B (zh) * | 2018-09-30 | 2020-11-06 | 北京鼎成肽源生物技术有限公司 | 一种rff2细胞 |
| WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| US12454562B2 (en) | 2018-12-06 | 2025-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatable cell surface receptors and related compositions and methods |
| GB201820157D0 (en) * | 2018-12-11 | 2019-01-23 | Imperial Innovations Ltd | Method of treatment |
| WO2020152197A1 (en) | 2019-01-23 | 2020-07-30 | Miltenyi Biotec B.V. & Co. KG | A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
| JP7602475B2 (ja) | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法 |
| EP3938387A1 (en) * | 2019-03-15 | 2022-01-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| JP2022531461A (ja) * | 2019-05-07 | 2022-07-06 | モデルナティエックス インコーポレイテッド | 免疫細胞活性を破壊するポリヌクレオチド及びその使用方法 |
| CN112279923B (zh) * | 2019-07-22 | 2023-07-18 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| MX2022002613A (es) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Metodos y composiciones para la integracion del genoma. |
| US20220401537A1 (en) * | 2019-09-16 | 2022-12-22 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| US20230151373A1 (en) * | 2019-10-23 | 2023-05-18 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Chimeric polypeptide for regulating immune cells |
| WO2021096868A1 (en) * | 2019-11-12 | 2021-05-20 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
| BR112022011399A2 (pt) | 2019-12-11 | 2022-08-30 | A2 Biotherapeutics Inc | Receptor de antígeno quimérico baseado em lilrb1 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| US20230100000A1 (en) | 2020-02-04 | 2023-03-30 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| US12286465B2 (en) | 2020-05-28 | 2025-04-29 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains |
| EP4161536A4 (en) | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| WO2021263211A2 (en) * | 2020-06-25 | 2021-12-30 | Houston Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| HUE067417T2 (hu) | 2020-08-20 | 2024-10-28 | A2 Biotherapeutics Inc | Készítmények és módszerek EGFR-pozitív rákok kezelésére |
| CN116724052A (zh) | 2020-08-20 | 2023-09-08 | A2生物治疗股份有限公司 | 用于治疗ceacam阳性癌症的组合物和方法 |
| MX2023002041A (es) | 2020-08-20 | 2023-04-27 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para mesotelina. |
| US20250019740A1 (en) * | 2020-10-26 | 2025-01-16 | Board Of Regents, The University Of Texas System | Mutant proteases and uses thereof |
| AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2022096664A1 (en) | 2020-11-09 | 2022-05-12 | Miltenyi Biotec B.V. & Co. KG | Methods and compositions for eliminating engineered immune cells |
| CN114807042B (zh) * | 2021-01-22 | 2024-09-03 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体改造的nk细胞及其制备方法与应用 |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| CA3218780A1 (en) | 2021-05-11 | 2022-11-17 | Daniel Getts | Methods and compositions for genomic integration |
| JP2023008482A (ja) | 2021-07-06 | 2023-01-19 | 日本たばこ産業株式会社 | たばこ製品の香味料担持構成部材及びこの製造方法 |
| WO2023044304A1 (en) * | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| US20250235477A1 (en) | 2021-10-06 | 2025-07-24 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| JP2024540058A (ja) * | 2021-11-04 | 2024-10-31 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 誘導性クラスターキメラ抗原受容体（ｃｃａｒ）構築物の開発 |
| EP4602171A1 (en) | 2022-10-15 | 2025-08-20 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| CN119331105B (zh) * | 2024-09-03 | 2025-10-28 | 中国人民解放军空军军医大学 | 靶向多种免疫检查点的通用多肽-protac及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| CA2223402C (en) * | 1995-06-07 | 2012-07-31 | University Of Pennsylvania | Methods of inhibiting phagocytosis |
| JP2000506007A (ja) | 1996-02-23 | 2000-05-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 細胞によるアッセイ |
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| US7060506B2 (en) | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
| GB0224442D0 (en) * | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| CN102070719A (zh) * | 2010-11-24 | 2011-05-25 | 中国人民解放军第四军医大学 | 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47 |
| EP4098275A1 (en) * | 2013-03-15 | 2022-12-07 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| RU2717984C2 (ru) | 2013-11-21 | 2020-03-27 | ЮСиЭл БИЗНЕС ЛТД | Клетка |
| HUE060047T2 (hu) * | 2014-10-09 | 2023-01-28 | Univ Yamaguchi | CAR expressziós vektor és CAR-t expresszáló T-sejtek |
| GB201620070D0 (en) | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| GB201717524D0 (en) * | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| JP7602475B2 (ja) | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法 |
| GB202007044D0 (en) * | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
-
2015
- 2015-06-01 GB GBGB1509413.9A patent/GB201509413D0/en not_active Ceased
-
2016
- 2016-05-31 ES ES16726416T patent/ES2791338T3/es active Active
- 2016-05-31 DK DK16726416.7T patent/DK3303568T3/da active
- 2016-05-31 PL PL16726416T patent/PL3303568T3/pl unknown
- 2016-05-31 HU HUE16726416A patent/HUE050132T2/hu unknown
- 2016-05-31 CN CN201680030192.8A patent/CN107667170B/zh active Active
- 2016-05-31 RU RU2017145074A patent/RU2729158C2/ru active
- 2016-05-31 EP EP20166710.2A patent/EP3730609A1/en not_active Withdrawn
- 2016-05-31 BR BR112017023190A patent/BR112017023190A2/pt not_active Application Discontinuation
- 2016-05-31 AU AU2016272457A patent/AU2016272457B2/en active Active
- 2016-05-31 KR KR1020177033957A patent/KR102275460B1/ko active Active
- 2016-05-31 PT PT167264167T patent/PT3303568T/pt unknown
- 2016-05-31 EP EP16726416.7A patent/EP3303568B1/en active Active
- 2016-05-31 JP JP2017562027A patent/JP6833727B2/ja active Active
- 2016-05-31 MX MX2017014630A patent/MX383118B/es unknown
- 2016-05-31 CA CA2986956A patent/CA2986956C/en active Active
- 2016-05-31 US US15/577,378 patent/US11345734B2/en active Active
- 2016-05-31 WO PCT/GB2016/051576 patent/WO2016193696A1/en not_active Ceased
-
2017
- 2017-10-27 ZA ZA2017/07334A patent/ZA201707334B/en unknown
- 2017-11-12 IL IL255594A patent/IL255594B/en active IP Right Grant
- 2017-11-30 CL CL2017003057A patent/CL2017003057A1/es unknown
-
2020
- 2020-05-18 JP JP2020086590A patent/JP2020115898A/ja not_active Withdrawn
-
2021
- 2021-11-12 US US17/525,244 patent/US20220267404A1/en active Pending
-
2022
- 2022-03-03 JP JP2022032551A patent/JP2022066380A/ja not_active Withdrawn
-
2024
- 2024-08-19 JP JP2024137629A patent/JP2024149818A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2986956C (en) | An immune cell comprising a car and truncated protein | |
| US12187769B2 (en) | Cell | |
| JP6538684B2 (ja) | 細胞 | |
| EP3612568A1 (en) | Cell | |
| US20190309046A1 (en) | Signal transduction modifying protein | |
| US20200338124A1 (en) | Cell | |
| US20200199550A1 (en) | Cell comprising a chimeric antigen receptor (car) | |
| CA3153847A1 (en) | Engineered immune cell | |
| NZ737662B2 (en) | Cell | |
| HK1246825B (en) | Cell | |
| BR122025000772A2 (pt) | Célula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210409 |